Pursuing novel therapeutics targeting NASH with liver fibrosis
Madrigal is a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases. Our most advanced clinical candidate, resmetirom, has the potential to become the first medication approved for the treatment of patients with non-alcoholic steatohepatitis (NASH) with liver fibrosis.
NEWS
January 06, 2023
Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver FibrosisDecember 21, 2022
Madrigal Pharmaceuticals Announces $300+ Million in Financing Events to Advance Resmetirom ProgramPRESS RELEASES >